Intuitive Surgical (NASDAQ:ISRG) EVP Sells $26,937.60 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Mark Brosius sold 61 shares of the business’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $441.60, for a total value of $26,937.60. Following the completion of the transaction, the executive vice president owned 581 shares in the company, valued at $256,569.60. The trade was a 9.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Brosius also recently made the following trade(s):

• On Monday, October 26th, Mark Brosius sold 61 shares of Intuitive Surgical stock. The stock was sold at an average price of $451.75, for a total value of $27,556.75.
• On Friday, September 11th, Mark Brosius sold 25 shares of Intuitive Surgical stock. The shares were sold at an average price of $365.79, for a total transaction of $9,144.75.
• On Wednesday, September 9th, Mark Brosius sold 23 shares of Intuitive Surgical stock. The shares were sold at an average price of $350.20, for a total transaction of $8,054.60.
• On Tuesday, September 8th, Mark Brosius sold 46 shares of Intuitive Surgical stock. The shares were sold at an average price of $361.23, for a total transaction of $16,616.58.
• On Friday, August 21st, Mark Brosius sold 77 shares of Intuitive Surgical stock. The stock was sold at an average price of $375.57, for a total value of $28,918.89.
• On Wednesday, August 19th, Mark Brosius sold 77 shares of Intuitive Surgical stock. The shares were sold at an average price of $394.26, for a total value of $30,358.02.
• On Monday, August 17th, Mark Brosius sold 77 shares of Intuitive Surgical stock. The shares were sold at an average price of $390.67, for a total value of $30,081.59.
• On Friday, July 31st, Mark Brosius sold 28 shares of Intuitive Surgical stock. The stock was sold at an average price of $351.00, for a total transaction of $9,828.00.

Intuitive Surgical Stock Down 3.7%

Shares of NASDAQ:ISRG opened at $432.01 on Friday. Intuitive Surgical, Inc. has a 52 week low of $328.57 and a 52 week high of $603.88. The stock has a market capitalization of $149.75 billion, a P/E ratio of 52.24, a PEG ratio of 3.09 and a beta of 1.46. The firm has a fifty day simple moving average of $401.54 and a two-hundred day simple moving average of $434.05.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The firm had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. During the same period in the prior year, the company earned $2.40 EPS. The business’s revenue was up 21.7% compared to the same quarter last year. On average, analysts expect that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ISRG shares. Wells Fargo & Company reissued an “overweight” rating and set a $486.00 target price (down from $487.00) on shares of Intuitive Surgical in a research report on Wednesday, October 21st. Evercore set a $430.00 target price on Intuitive Surgical in a research report on Monday, July 6th. HSBC lowered Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 price target for the company. in a research note on Thursday, July 30th. TD Cowen reiterated a “buy” rating and set a $485.00 target price on shares of Intuitive Surgical in a research report on Monday, October 19th. Finally, KeyCorp restated an “overweight” rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $493.54.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. 3Chopt Investment Partners LLC grew its stake in Intuitive Surgical by 26.5% during the 3rd quarter. 3Chopt Investment Partners LLC now owns 711 shares of the medical equipment provider’s stock worth $289,000 after buying an additional 149 shares during the last quarter. Focused Wealth Management Inc acquired a new position in shares of Intuitive Surgical during the third quarter valued at about $242,000. Rakuten Investment Management Inc. increased its holdings in shares of Intuitive Surgical by 10.2% during the third quarter. Rakuten Investment Management Inc. now owns 94,113 shares of the medical equipment provider’s stock valued at $38,791,000 after acquiring an additional 8,725 shares in the last quarter. Provenance Wealth Advisors LLC boosted its stake in Intuitive Surgical by 808.4% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 4,778 shares of the medical equipment provider’s stock worth $1,943,000 after purchasing an additional 4,252 shares in the last quarter. Finally, Hughes Financial Services LLC grew its position in Intuitive Surgical by 40.7% during the 3rd quarter. Hughes Financial Services LLC now owns 83 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 24 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.